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Blockade of the renin-angiotensin system (RAS) is now recognized as an effective 
means of lowering blood pressure (BP) and protecting hypertensive patients from 
end-organ damage. There are nowadays three pharmacologic approaches to blockade 
of the RAS: with angiotensin-converting enzyme (ACE) inhibitors, introduced in the 
170s, with angiotensin II (Ang II) AT1 receptor blockers (ARBs), introduced in the 
10s, and with direct renin inhibitors, a new class whose first agent, aliskiren, was 
introduced in 2006. Clinical studies with the first two classes have shown that neither 
one achieves complete blockade of the RAS. With chronic use of ACE inhibitors, there 
is a gradual return of Ang II towards pretreatment levels because enzymes other than 
ACE (e.g., chymase and others) can cleave off two aminoacids from the decapeptide 
Ang I, even though there is no evidence of “escape” in terms of BP control. With 
ARBs there is a partial blockade of AT1 receptors of variable degree and duration, 
depending on the affinity of each agent for the receptor and of the duration of the 
blockade (surmountable or insurmountable).
It has now been shown that an almost complete blockade of the RAS can be 
achieved by combination of an ACEI + ARB (Hypertension 2003; 41:31-36). There has 
been clinical evidence that a more complete blockade of the RAS may offer benefits 
in terms of end-organ protection even beyond those of optimal BP control, e.g. by 
arresting or reversing the progression of diabetic or other nephropathies (The Lancet 
2003; 361:117-124). One such trial, the ONTARGET study of telmisartan + ramipril 
combination presented recently at the ACC meeting (Chicago, 2008), showed that 
combination of the two agents achieved a small additional BP lowering compared to 
monotherapy with either one. Not surprisingly, telmisartan tended to be better toler-
ated than ramipril. However, there was no advantage with the combination in terms 
of outcome; in fact, there was a trend to increased adverse reactions, especially renal 
impairment, which was puzzling. Nevertheless, these data are not much different from 
those reported in the past for treatment of acute myocardial infarct with valsartan 
and captopril alone or in combination (the VALIANT study). This is in contrast to 
two heart failure studies of ACEI + ARB combinations, the Val-HeFT and CHARM 
trials, in which the ARBs valsartan and candesartan, respectively, showed additional 
benefits when added to ACE inhibitor therapy.
A complete blockade of the RAS can also be obtained by combination of an ARB 
with a renin inhibitor. One such study (The Lancet 2007, 370: 221-22) demonstrated 
that combination of the ARB valsartan with the renin inhibitor aliskiren, produced 
a significantly greater BP decrease than either agent given as monotherapy. Such 
combination would be particularly desirable in cases, where total suppression of the 
RAS is desirable, but the patient is intolerant to ACE inhibition (because of cough 
or angioedema). Further outcome trials are needed to show whether ARB + renin 
inhibitor combination offers additional long-term advantages in terms of end-organ 
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protection when compared to different drug combinations 
achieving the same degree of BP lowering.
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